The JAK-STAT signal transduction pathway is responsible for mediating signals of over fifty cytokines, growth factors and hormones. Signaling through the JAK-STAT pathway is regulated on multiple levels, including intramolecular regulation by the JAK pseudokinase domain, and intermolecular regulation by a host of regulatory proteins. The advent of accessible genomic tools have provided a wealth of information on disease-associated mutations in the JAK-STAT pathway and its regulatory components. The vast number of these mutations in diseases ranging from immunodeficiencies and obesity to many cancers highlight the importance of correct regulation of JAK-STAT signaling for biological processes such as hematopoiesis, regulation of the immune system, metabolism, and growth. Simultaneously, JAK inhibitors are gaining traction in clinical use, both for treatment of diseases driven by JAK mutations, and for a host of inflammatory disorders, in which proinflammatory cytokine signaling through the JAK-STAT pathway is an integral part of pathogenesis. The elucidation of molecular mechanisms in the pathogenesis of complex diseases has also, however, brought the limitations of our current understanding on the regulation of cytokine signaling to the foreground. Indeed, deeper understanding of these regulatory mechanisms are a prerequisite for the development of the next generation of pharmacological modulators of the JAK-STAT pathway. In this review we discuss the current state of knowledge of the intra-and intermolecular regulation of the JAK-STAT pathway, with a focus on diseases arising from disruptions in the regulatory apparatus.
Introduction
Hematopoietic cytokines play a critical role in orchestrating fundamental processes such as the immune response and hematopoiesis, but also cell differentiation and growth. Thereby it is not surprising that the central cytokine signaling pathway through Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) transcription factors has been shown to either cause or participate in tumorigenesis. The first demonstration of this were the identification of rare oncogenic fusions involving the JAK kinase domain, e.g., the TEL/ ETV6-JAK2 translocation resulting in leukemia driven by constitutively dimeric and active JAK2 kinase domain [1] . Subsequently, several other JAK2 fusions have been identified [2] as well as JAK2 gene amplifications in lymphomas [3] and triple-negative breast cancer [4] . Nevertheless, somatic JAK driver mutations are most commonly found in hematological malignancies, where a single oncogenic JAK2 mutation, JAK2 V617F, underlies more than half of all classical myeloproliferative neoplasm (MPN) cases (reviewed in [5, 6] ). JAK mutations are also common in leukemia, where, e.g., somatic JAK1 mutations are found in 10-20% of T-cell acute lymphoblastic leukemia (T-ALL) and JAK2 mutations in ∼ 20% of down syndrome-associated B-ALL [5] .
Recently, (epi)genetic changes in JAKs, STATs, as well as regulatory components of the pathway have also been increasingly linked to other Table 1 Type I and II cytokines, their receptor chain configurations, as well as the corresponding JAKs and STATs are shown. JAKs and STATs critical for signaling identified with the highest confidence are shown in bold, associated JAKs and STATs for which the data is weaker are shown in parentheses. Cytokines that signal through the same receptor-JAK-STAT configuration are separated by commas. Synonyms are separated by a slash. In case of three or more often-used synonyms and for additional explanations, see footnotes. Cytokine Receptor [7] ). Furthermore, several cytokines, particularly interleukin (IL-)6 mediate critical signals for the growth of solid tumors, and inhibition of JAK kinases by small-molecular weight inhibitors has been shown to efficiently abrogate tumor formation or restore sensitivity to other protein tyrosine kinase (PTK) inhibitors in xenograft models [8, 9] . Currently, clinical JAK inhibition is focused on the treatment of MPNs [10] and rheumatoid arthritis (RA) [11] , and clinical trials with JAK inhibitors are ongoing also in other autoimmune and inflammatory diseases [12] . Mounting evidence of the involvement of the JAK-STAT pathway in cancer, however, has already led to clinical trials with JAK inhibitors in, e.g., pancreatic cancer [13] , advanced solid tumors (ClinicalTrials identifier: NCT02646748), NSCLC (NCT02917993), and triple-negative breast cancer (NCT02876302). The majority of clinical JAK mutations concentrate in the pseudokinase domain of the protein and highlight the importance of understanding the molecular mechanisms of normal and pathogenic JAK signaling. Given the prevalence of JAK mutations as well as the broad involvement of JAK-mediated signaling in disease, this understanding is a vital prerequisite for developing better future therapies with potential for wide-ranging implications. In this review, we discuss the current views on the molecular basis of regulation of JAKs, as well as mechanisms of JAK deregulation in disease.
Jaks and the JAK-STAT pathway
JAKs are intracellular, non-receptor PTKs, but constitutively associated with their cognate receptors [14] [15] [16] . There are four JAKs in mammals, birds, and fish (JAK1-3, TYK2), with JAK1, JAK2 and TYK2 being ubiquitously expressed, while expression of JAK3 being mostly restricted to cells of hematopoietic origin [17] . JAKs are multi-domain proteins consisting of an N-terminal FERM-domain, a SH2-like domain, a so-called pseudokinase domain (JAK homology 2, JH2) and the catalytically active, signaling PTK domain (JH1). The FERM and SH2-like domains mediate the interaction of JAKs with their receptors [18, 19] , as well as regulating JAK kinase activity by as-of-yet unknown mechanisms [20, 21] . Recent crystal structures have revealed that the FERM and SH2 domains form a structurally tightly-linked continuous unit with the receptor peptide running over, and intimately contacting both domains [22] [23] [24] [25] .
The most defining JAK domain is probably the pseudokinase domain, JH2, which constitutes the second kinase domain, and thus the second face of its two-faced namesake ancient Roman god Janus. JH2 strongly resembles eukaryotic protein kinases, but shows a distinct pattern of deviations from active kinases including lacking the catalytic aspartate, which is replaced by an asparagine in all JAK JH2s, thus gaining them the classification of 'pseudokinase' [26] [27] [28] . JH2 has critical regulatory functions, and is a veritable hotspot for clinically relevant mutations, including driver mutations underlying hematopoietic malignancies (JAK2 mutations), leukemia and lymphomas (all JAKs), and cancer (JAK1, JAK3), discussed in more detail below [5] . Lastly, JAKs consist of a C-terminal active PTK domain, JH1 , which is closely related to the kinase domain of receptor tyrosine kinases (RTKs), like epidermal growth factor receptor (EGFR), and seems to be evolutionarily distinct from JH2 [29] .
JAKs mediate signaling of around sixty different cytokines, hormones, and growth factors ranging from regulators of the immune system and hematopoiesis, like interleukins (IL), interferons (IFN), erythropoietin (EPO), and thrombopoietin (TPO), to regulators of development and metabolism, like prolactin (PRL) and growth hormone (GH) (see Table 1 ) [30] . Signaling through the JAK-STAT pathway (Fig. 1A) is initiated by binding of a cytokine to the extracellular Table 3 . C) The JH2-JH1 inhibitory interaction using JAK2 as an example [44] . Sites of known clinical activating JAK2 mutations are shown with red spheres (α carbon), and most important mutations are highlighted. The two inhibitory phosphorylation sites, pS523 and pY570, are encircled. D) Close-up of the D873-R683 interaction, along with surrounding residues, all of which are known sites of activating mutations ( Table 2 ). E) The phenylalanine stack around F617 in JAK2 V617F crucial for V617F-induced JAK2 activation. portions of its cytokine receptor chain(s). This induces dimerization, oligomerization, or a conformational change of the receptor complex [31] , which activates associated JAKs inducing trans-autophosphorylation of the activation loop (AL) of JAK JH1s [32] and a subsequent increase in catalytic activity [33] . The molecular details of this activation mechanism are still unknown with multiple competing models currently under investigation (see below) [34] . Activated JAKs next phosphorylate specific tyrosines on the receptor chains, which serve as docking sites for SH2 domain-containing signaling molecules like STATs [35] . Receptor-bound STATs are next phosphorylated by JAKs on a specific tyrosine in the C-terminal tail, enabling SH2-mediated dimerization of STATs, and subsequent translocation into the nucleus [35] [36] [37] , where they act as transcription factors with far-reaching effects on regulation of transcription and epigenetics (reviewed in [38] ). This simple signal transduction pathway of cytokine receptors, associated JAKs, downstream STATs, along with key protein regulators is evolutionarily conserved throughout bilateria [39] .
Regulation of JAK activity
Activity of the JAK-STAT pathway is tightly regulated on multiple levels to ensure suppression of signaling in the absence of cytokine stimulation, but also to allow rapid, transient activation upon stimulation ( Fig. 1 ). Regulation relies primarily on control of JH1 tyrosine kinase activity by intra-and intermolecular mechanisms, as well as on controlling the availability of parts of the signaling machinery. Many of these levels of regulation are initiated or modulated by phosphorylation of regulatory residues on JAKs, receptors, and STATs
Intramolecular regulation of JAK activity
The most basic level of regulation of JAK tyrosine kinase activity is by the AL of JH1. Isolated JH1, when produced using recombinant protein technology, is constitutively active and able to autophosphorylate its AL in solution leading to full activation of the domain's enzymatic activity [33, 40, 41] . In PTKs, this phosphorylation is usually necessary to relieve inhibition caused by the insertion of the unphosphorylated AL into the active site of the domain [42] . However, no crystal structures of JH1 currently exist of this presumed inactive form [43] , and recent molecular dynamics data have suggested, that activation of JH1 via phosphorylation of its AL is not (only) due to vacation of the active site, but rather, due to destabilization of the autoinhibitory JH2-JH1 interaction [44] .
Inhibition and activation of JH1 by JH2
Early domain deletion experiments indicated that both JH2 and JH1 were needed for JAK-mediated signaling [45] [46] [47] [48] . Subsequently, work on JAK2 and JAK3 found that loss of JH2 was also associated with increased basal JAK activity (i.e. in the absence of cytokine stimulation) [47, 48] . Furthermore, adding JH2 to isolated JH1 in cells or in recombinant constructs has been shown to significantly decrease kinase activity of JH1 [40, 41, 47, 49] . Thus, JH2 is a regulatory domain with two roles: firstly, inhibition of the kinase activity of JH1 in the absence of stimulation and, secondly, mediation of the stimulatory signal from the cytokine receptor to JH1 [48] . Both of these functions are strikingly apparent in the effects of various known clinical and experimental JAK mutations, as JH2 harbors both gain-of-function and loss-of-function mutations [46, 50] (see Table 2 ).
Recently, virtually identical structures of a JH2-JH1 interaction were proposed by long time scale molecular dynamics simulations for JAK2 [44] and a crystal structure for TYK2 [41] , which provide explanation for JH2-mediated inhibition of JH1 (Fig. 1C ). In the interaction, JH2 binds to the hinge-side of JH1 in a front-to-back orientation, loosely analogous to the interaction seen in the autoinhibited structure of Src kinase, in which SH2-SH3 domains bind to the hinge-side of the kinase domain [51] . In the JH2-JH1 interaction, JH1 activity is probably inhibited by an opening of the catalytic site and conformational restriction of the JH1 lobes preventing the conformational dynamics of JH1 needed for the kinase reaction.
The simulation-derived, autoinhibitory JAK2 JH2-JH1 interaction includes two previously known, JAK2-specific inhibitory phosphorylation sites: JAK2 S523 and Y570 [52] [53] [54] [55] (Fig. 1B , Table 3 ), phosphorylation of both of which is expected to strengthen the interaction (Fig. 1C ) [44] .
Activation of JAKs by mutation
The inhibitory JH2-JH1 interaction interface harbors the majority of known clinical and experimental activating JAK mutations, and disruption of the inhibitory interaction thus provides an explanation for the hyperactive phenotype. Striking examples are mutations in JAK2 JH2 β7-β8 and αC-β4, and JH1 β2-β3 loops, which contain JAK2 R683 and D873 that form an ionic interaction over the JAK2 JH2-JH1 interface ( Fig. 1D ). Mutations in these loops (including mutations of R683 and D873 themselves) are expected to weaken the JH2-JH1 interaction by disrupting the R683-D873 link. Similarly, these residues are also known mutation sites in other JAKs ( Table 2) , indicating that the identified mode is likely to be conserved across all four JAKs. The multitude of known JAK2 exon 12 mutations (Table 2) , on the other hand, fall into the SH2-JH2 linker region, which probably makes extensive contacts along the JH2-JH1 interface [44] , and has previously been shown to be important in suppression and regulation of basal activity [19, 56] . Similarly, mutations such as JAK2 V617 are expected to disrupt the conformation of the SH2-JH2 linker, which is probably (at least part of) the activation mechanism of, e.g., JAK2 V617F.
However, it is currently unclear, whether the high activating potency of, e.g., JAK2 V617F is explained by SH2-JH2 linker-mediated disruption of the JH2-JH1 interaction alone, or whether a distinct activating intra-or intermolecular interaction is involved. Indeed, analysis of recombinant JAK2 fragments has shown that introduction of V617F to JH2-JH1 constructs only increases catalytic activity by ∼3fold [40] , suggesting that another mechanism beyond disruption of the JH2-JH1 might be needed to explain the abnormally high activity of JAK2 V617F in vivo. CoIP experiments with full-length JAK2 have suggested that addition of the V617F mutation leads to a JAK2-JAK2 interaction in vitro, which cannot be detected with wild-type JAK2 [57] . The high density of activating mutations in the N lobe of JH2 as well as the SH2-JH2 linker has also been suggested to be circumstantial evidence for an activating interaction, probably involving these regions [58] . Transformation by practically all activating JAK2 mutations (including JAK2 V617F) requires the presence of cytokine receptors [59] [60] [61] , which could be due to requirements for an activating transinteraction. Alternatively, the receptor could function as a simple scaffold allowing co-localization of activated JAKs with their substrate (s). Data showing that correct orientation of the receptor chains are not needed for activation by JAK2 V617F [62] support the latter model.
Analysis of experimental mutations capable of inhibiting activation by clinical disease mutations (e.g., JAK2 V617F) has identified regions in JH2 required for mutational activation. These regions include the SH2-JH2 linker [63] , a functional ATP-binding pocket in JH2 (at least in JAK1, JAK2 [64] , and JAK3 (Raivola, Hammarén, Silvennoinen et al, manuscript in preparation)), as well as JH2 αC [62, 65, 66] . Indeed, molecular dynamics simulations of JAK2 JH2 suggest that V617F induces stabilization of JH2 αC, which can be reversed by addition of the inhibiting αC mutation JAK2 F595A thus breaking the phenylalanine stack around F617 (Fig. 1E ) [67] . Similarly, loss of JH2 ATP-binding is likely to suppress mutational activation by destabilizing αC [64] . Interestingly, these mutations have been reported to not strongly inhibit cytokine-dependent JAK activation, suggesting that activation by cytokine could be mechanistically distinct from activation by mutations like JAK2 V617F [57, 62, [64] [65] [66] . Whether this is due to a distinct Table 2 Clinical mutations in JAKs. Data in the table were expanded from similar compilations in [41, [165] [166] [167] . Kinase activitymeasured as basal JAK activation loop phosphorylation (e.g., JAK2 Y1007/1008), STAT phosphorylation, or transcriptional activity in reporter assay: +/− increase/decrease in activity, respectively. An increase in activity (+) refers to basal (unstimulated) activity (e.g., ligand-independent activation by JAK2 V617F); for decreased activity (−) signaling upon stimulation is included (e.g., cytokine-irresponsive JAK3 SCID mutations); NEno appreciable effect. fsframe-shift. Due to the increased pace of genetic analysis of patient samples, experimentally uncharacterized mutations are only shown, if of special interest. [186] (continued on next page) JH2 C565X − SCID [108, 198] (continued on next page) [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] activating interaction employed by, e.g., JAK2 V617F, is still unknown.
Phosphorylation as mediator of regulation
Much of the regulation of JAK-STAT signaling is controlled by phosphorylation (Fig. 1B) . In the basal state, JAK2 (for which there is the most data available) is phosphorylated only on S523 (potentially by JH2 itself [54, 68] ), which strengthens the JH2-JH1 interaction described above [44] . Upon activation of receptor by cytokine, JAK2 is activated by (trans-)autophosphorylation not only on the JH1 AL (Y1007/Y1008), but also on multiple other residues (Y637, Y868, Y966, Y972), which are needed for full activation of kinase activity by as-of-yet unknown mechanisms (Table 3 ) [69] . Termination of signaling is subsequently initiated by phosphorylation of numerous inhibitory residues along JAK2 (Fig. 1B, Table 3 ), which may cause dissociation of JAK2 from its receptors (Y119 [70] ), strengthen the JH2-JH1 inhibitory interaction (Y570, Fig. 2C [44,68,69] ), or act as binding sites for regulatory proteins.
Likewise, dephosphorylation of both JAK and receptor activating tyrosines is an important part of regulation of signaling, and is induced by multiple protein tyrosine phosphatases (PTP), including SH2 domain-containing phosphatases 1 and 2 (SHP1, SHP2), PTP1B, T-cell-PTP (TCPTP), Receptor-type PTPs C (PTPRC/CD45) and T (PTPRT), as well as basophil-like PTP (PTPBL) (reviewed in [71] ). Notably, SHP2, which is a known oncoprotein and increasingly interesting drug target itself [72] , has been reported to be both an activator and suppressor of JAK-STAT signaling depending on the context [71] . Other phosphatases associated with regulation of JAK-STAT signaling function as classical negative regulators of signaling in termination or basal suppression of signaling (reviewed in [34, 71] ). Most recorded phosphorylation events on JAK2 have been shown to be dependent on JAK2 JH1 kinase activity (or AL phosphorylation), but the exact sequence of phosphorylation events or their mechanism of action during receptormediated activation is yet to be fully elucidated. Potential differences in phosphorylation-mediated regulation in different cytokine receptor-JAK contexts also remain mostly unknown.
Intermolecular regulation of JAK activity
Most known intermolecular modes of JAK-STAT signaling regulation are involved in termination of signaling after cytokine stimulation, and are thus initiated by phosphorylation during cytokine-mediated Table 3 Regulatory phosphorylation sites, their effect on basal JAK2 activity (measured as pJAK2 (pY1007/Y1008) or a downstream measure like STAT phosphorylation (pSTAT) or transcriptional reporter activity), the probable phosphorylating kinase, and assumed effects of phosphorylation (mostly based on mutagenesis experiments) are shown. Cytokines, which have been experimentally tested for inducing specific phosphorylation, are shown in parenthesis. Sites for which no functional follow-up data has been published, have been omitted for clarity (see, e.g. [234, 235] * Dependent on JAK2 Y1007/Y1008 phosphorylation and/or JH1 kinase activity. § Y201F has no effect on EPO-induced pJAK2, but inhibits Ang II-mediated pJAK2, pSTAT1/3. Phosphorylation probably enables binding of SHP2 and subsequent binding to AT1 receptor. Y201F has also been shown to inhibit activation by JAK2 V617F [236] . activation. Mechanisms of termination involve (de)phosphorylation, production of inhibitory proteins, and removal of signaling complexes through internalization and lysosomal or ubiquitination-mediated proteasomal degradation of receptors [5, 34] . One family of direct inhibitory proteins are suppressors of cytokine signaling (SOCS1-7 and CIS), transcription of which is upregulated by activated STATs, thus forming a negative feedback loop [73] . The mechanism for SOCS-mediated inhibition has been revealed for SOCS3, which binds to both JH1 and the associated cytokine receptor, leading to inhibition of JH1 activity by direct interaction with the JH1 AL, in addition to initiation of ubiquitination of JAKs [74, 75] .
Active JAK-STAT signaling also induces transcription of SH2B family proteins (consisting of SH2B1/SH2-B, SH2B2/APS, and SH2B3/ LNK), which each consist of a dimerization domain (DD), Pleckstrin homology (PH) domain and a C-terminal SH2 domain. SH2-B and APS bind to phosphorylated receptor or JAK tyrosines (e.g. JAK2 pY613 and pY813) via their SH2 domain [76] [77] [78] [79] , and are able to either activate or inhibit JAK activation, potentially by acting as dimerization scaffolds for JAKs [80] . The activating role of SH2-B has been most comprehensively demonstrated in leptin-JAK2 signaling [78, 81] , and mutations or deletions in SH2B1 have been linked to severe obesity (see Table 4 ). Interestingly, SH2-B has also been reported to bind to EPOR and putatively act as a negative regulator of EPOR signaling [82] . The third SH2B family member, LNK is a well-defined inhibitor of JAK2, as well as potentially JAK3 (reviewed in [79] ). How LNK negatively regulates JAK activity is not clear, but it is likely to involve a direct interaction with the LNK N-terminal domains and JAK kinase domains, and/or ubiquitination via recruitment of E3 ligases [79] .
JAK-STAT signaling is also regulated at the level of STATs by protein inhibitor of activated STATs (PIAS) proteins, which are one of only few known small ubiquitin-like modifier (SUMO) E3 ligases (see [83] for a review). As their name suggests, PIAS proteins (consisting of PIAS1, PIAS3, PIASx, and PIASy) were first identified as negative regulators of STATs [84, 85] , but they have since been shown to also be involved in regulation of multiple other cellular processes [86] . Following cytokine stimulation, PIAS proteins have been shown to inhibit STAT signaling activity through inhibition of their DNA-binding activity by directly interacting with STATs and and/or by inducing STAT SUMOylation (reviewed in [87] ).
Activation of JAKs by cytokines -The role of the cytokine receptor
Despite long-continuing research into the mechanisms of JAK activation by mutation and intermolecular regulation by various negative regulator proteins, the molecular mechanisms of JAK activation on cytokine receptors following cytokine stimulation have mostly remained elusive. One complicating factor is the sheer number of different JAK-associated receptors ( Table 1) and their variable architectures. These range from 'short receptors' (e.g., GHR, EPOR, γ c family, IFNGR) where ligand-binding domains are proximal to the membrane, and 'tall receptors' (e.g., gp130, TCCR, LIFRβ) with ligand-binding domains up to 10 nm removed from the membrane [88] [89] [90] [91] . Numerous crystal structures of receptor extracellular domains have been generated showing cytokine-bound and unbound states [90] , but how these changes are translated into intracellular activation of JAKs is not known.
The simplest mode of cytokine receptor activation is an induced dimer/oligomer model, where ligand binding induces dimerization/ oligomerization of receptor chains and associated kinases, which are subsequently activated by transphosphorylation due to proximity. This mode is widely seen in RTKs [92, 93] , with exceptions like insulin receptor kinase (IRK), which seems to exist as preformed dimers rearranged by ligand binding [94] . Studies with engineered artificial chimeric receptors have shown that simple dimerization is sufficient to activate JAKs [95] suggesting an induced-dimer activation model. Nevertheless, preformed dimers have been reported for many JAK-associated receptors, including EPOR [96] , GHR [97] , gp130 [98] , LEPR [99] , as well as IL-2Rβ/IL-9Rα and γ c [100] . However, some of these data may be confounded by the use of artificial overexpression systems and/or dimerization-prone fusion proteins. A current lack of methods to simultaneously measure receptor oligomerization and activation states also leaves it unclear, how many of the observed preformed dimers are actually actively signaling and thus contributing to basal signaling activity. Still, studies with forced EPOR or TPOR dimers have indicated that correct orientation of receptor chains is needed for activation of wild-type JAK2, thus potentially enabling non-signaling preformed dimers in vivo [101] [102] [103] . Additionally, FRET-studies with forced preformed GHR dimers suggested that the intracellular portions of GHR would move apart during stimulation, leading the study authors to hypothesize that JH2-mediated inhibition of JH1 could occur in trans at least for JAK2 [104] . How, or whether this architecture would apply to heteromeric JAK configurations, is unclear.
Despite these earlier findings, recent single-molecule imaging studies have shown a distinct lack of preformed dimers for EPOR at least, and approaches using engineered protein ligands have suggested that activation of EPOR-JAK2 is mainly determined by the distance between receptor chains [105] , thus again arguing for a ligand-induced dimer model [91] . Further research using less invasive methodology with (at least close to) native expression levels of receptors is thus sorely needed to settle the question of receptor-mediated activation of JAKs.
Failure of JAK regulation leads to disease
Failure of JAK-STAT pathway regulation is a common cause of myeloid and lymphoid disorders but also plays a role in multiple cancers (Table 4) [6, 7, 106] . The first JAK disease-link was discovered in 1995 when JAK3 loss-of-function mutations were reported causative of severe combined immune deficiency (SCID) [107, 108] . Shortly later, inhibition of acute lymphoblastic leukemia (ALL) with JAK-inhibitor AG-490 lead to the discovery of constitutive JAK2 activity in patientderived ALL cells [109] . Subsequently constitutively active JAK2 fusion protein TEL/ETV6-JAK2 was identified in early pre-B cell ALL and Tcell childhood ALL [1, 110] .
Oncogenic JAK2 rearrangements to multiple fusion gene partners (TEL, PCM1, BCR, SSPB2, STRN3, RPN1, NF-E2, RUNX1, SEC31A, SPAG9) have since been identified in ALL, acute myeloid leukemia (AML), atypical chronic myeloid leukemia (CML), MPN and/or Hodgkin lymphoma [2, [110] [111] [112] [113] [114] , and similar oncogenic fusions have also been reported for TYK2 [106] . The chimeras comprise of JH1, with or without (pieces of) JH2, fused to dimerization domain(s) of the fusion partner, leading to constitutive tyrosine kinase activity presumably via dimerization/oligomerization [1, 112, 115] . These translocations are rare, however: a cytogenetic study of 24 262 unique patients, for example, revealed these kinds of JAK2 abnormalities in only 0.06% of hematopoietic neoplasms [113] .
In contrast, somatic JAK2 V617F is highly prevalent in MPN and causes approximately 95% of polycythemia vera (PV) and 50-60% essential thrombocythemia (ET) and primary myelofibrosis (PMF) cases [116] [117] [118] [119] . Allelic burden probably plays a role in defining the clinical phenotype of JAK2 V617F as the burden increases from ET over PV to PMF [120] . Furthermore, the pSTAT profiles discriminate among the MPN diseases and are independent of JAK2 V617F: high pSTAT3 and pSTAT5 are typical in PV, high pSTAT3 and low pSTAT5 in ET, and low pSTAT3 and pSTAT5 in PMF [121] , but the mechanism behind these differences have remained largely unknown. PV, ET and PMF can evolve into AML and therefore it is not surprising that approximately 5% of AML patients are also V617F-positive [122] . Numerous gain-offunction mutations identified in JAK1, JAK2 and JAK3 (Table 2) are drivers in ∼20% of T-ALL cases (mainly JAK1, also JAK2, JAK3) and to lesser extent in B-ALL (JAK1, JAK2) or hepatocellular adenoma (JAK1) [5, 123] .
V617F-negative MPN often show mutations in other components or Table 4 Diseases caused by failure in JAK regulation. See Table 2 for a full list of disease-associated JAK mutations. See list of abbreviations for explanations of abbreviations.
Mode of regulation disrupted
Example(s) Associated disease / clinical phenotype
Reference
All levels of regulation Activating JAK2 chimeras (e.g. TEL-, PCM1-, BCR-, SSBP2-, STRN3-, SEC31A-JAK2) T-ALL; B-ALL; atypical CML; Hodgkin lymphoma (SEC31A-JAK2); MPNs [2, [110] [111] [112] [113] 115] JAK3 deficiency (truncations, destabilizing mutations) SCID [131] TYK2 deficiency (truncations) PID [132, 133] Catalytically inactive TYK2 JH1 variant P1104A Decreased susceptibility to autoimmunity and RA [231, 232] Intramolecular Inhibition of JH1 by JH2 Activating JAK JH2 mutations (e.g. JAK2 V617F, JAK2 R683G, JAK1 R724H, JAK3 M511I) presumably disrupting the JH2-JH1 inhibitory interaction MPNs; lymphoid and myeloid leukaemia: T-ALL, B-ALL, AML, AMKL, T-PLL, JMML, NTCL, NKTCL; hepatocellular carcinoma (JAK1) [41, 116, 123, 166, 168, 213, 216] Inhibition of JH1 by FERM Activating JAK3 FERM mutations (E183G, L156P, R172Q) ATLL [206] Activation of JH1 by JH2 Inactivating JAK3 JH2 mutations (e.g. C759R) SCID [49] Inactivating TYK2 JH2 variant I684S Decreased susceptibility to autoimmunity and RA [231, 232] Intermolecular T-ALL [248] LOF mutation in PTPRC T-ALL [249] Activation by PTP (SHP2) GOF mutations in SHP2 presumably resulting in increased signaling † Noonan syndrome; Lymphoid and myeloid leukemias: JMML, AML, B-ALL; Solid cancers: Breast, lung, gastric, and neuroblastoma; MDS [250, 251] Receptor-mediated Regulation of receptor conformation Activating TpoR receptor mutations MPL S505N, MPL W515 (L/K/A) Hereditary thrombocythemia; V617F-negative MPN [252, 253] Activating IL7R mutations (S185C, TM-domain) T-ALL; B-ALL; SCID [176, 254, 255] JAK-receptor interaction Inactivating JAK3 receptor-binding deficient mutant Y100C SCID [201] Intermolecular CALR mutations (e.g. p.L367fs*46, a 52-bp deletion) enabling direct binding and activation of TPOR V617F-negative MPN [128, 256, 257] † Suggested to activate Ras/ERK1/2 pathway, but SHP2 has also been shown to regulate PI3K/AKT, JAK-STAT, JNK, and NF-κB signaling [72] .
regulatory elements of the JAK-STAT pathway. For example, 1-5% PMF and ET patients carry point mutations (e.g., S505N, W515L/K/R) in the thrombopoietin receptor (TPOR) gene MPL [124] , which enable ligand-independent activation of TPOR-JAK2 signaling [125, 126] . Relatively common are also calreticulin (CALR) frameshift mutations causing TPO-independent TPOR-JAK2 signaling in up to ∼13% of MPNs. CALR is a multifunctional endoplasmic reticulum protein, and its common frameshifts result in the formation of a highly-charged protein structure at the C-terminus of mutated CALR, which has been shown to be able to directly bind to the ligand-binding domain of TPOR, thus activating the receptor [127, 128] . Another MPN-linked activation mechanism through TPOR is caused by mutations in the inhibitory adaptor protein LNK, which lead to mislocalization of LNK from the plasma membrane into the cytoplasm and result in TPO hyper-responsiveness [129] . LNK mutations are found in 5-7% of MPNs [130] .
Besides disease-causing mutations hyperactivating JAK-STAT signaling, also deleterious loss-of-function mutations in the JAK-STAT regulatory apparatus have been described. Probably most famously, loss-of-function (LOF) germline mutations in JAK3 or JAK3-associated receptors IL-7R and common gamma chain (γ c ; also known as CD320 or IL-2RG) cause autosomal recessive SCID [131] . In fact, JAK3/IL-7R/γ c mutations cover the majority of all SCID cases: JAK3 mutations account for approximately 10-18% of heritable SCID, IL-7R < 10%, and γ c 25-46% [131] . Although JAK3 SCID-associated mutations are found in all JAK domains, the majority is located either in JH2 or the FERM domain ( Table 2 ). Known JAK3 mutations include frameshifts and nonsense mutations (readily explaining LOF), but interestingly also point mutations, for all of which the mechanism action has not been conclusively determined (Table 2) . Some JAK3 mutations are, however, known to affect protein expression and structural stability, or less commonly hinder receptor binding (e.g. JAK3 Y100C) [131] .
Knowledge about diseases caused by TYK2 mutations has only lately started to emerge. TYK2 deficiency caused by frameshift mutations has been reported in two primary immunodeficiency (PID) patients, one with and one without hyper-IgE syndrome [132, 133] . Activating driver TYK2 mutations have recently been found in multiple ALL cell lines [134] and patient samples, including two gain-of-function germline TYK2 mutations [135] . Additionally, multiple TYK2 polymorphisms have been described, some of which alter the activity of the protein and are associated with increased or decreased risks for autoimmune or inflammatory diseases ( Table 2) .
SOCS as regulators of JAK-STAT pathways have critical functions in pathogenesis of inflammatory and other immune disorders, susceptibility to infectious diseases and development and progression of cancer [136, 137] . SOCS are suggested to have tumor suppressive role and decreased SOCS levels due to DNA hypermethylation of one or more SOCS genes have been observed in multiple cancers, such as hepatocellular carcinoma, cholangiocarcinoma, Hodgkin lymphoma, and primary mediastinal B-cell lymphoma. Furthermore, reduced expression of SOCS3 was shown to associate closely with lymph node metastasis in breast cancer [138] . Elevated SOCS levels possibly caused by certain SOCS promoter variants have been found in asthma (SOCS1, 3), RA (SOCS1, SOCS3), and atopic dermatitis (SOCS3) [136, [139] [140] [141] .
Although outside of the scope of this review, the role of various STAT mutations in development of immunological diseases cannot be underestimated as they lead to similar clinical phenotypes as deregulation of the upstream components. For recent reviews see [142, 143] .
Future outlook and perspectives
Current clinical and pharmacological interest in JAKs is at an alltime high. JAK inhibition has proven to be effective not only in diseases directly caused by activating deregulation of the JAK-STAT pathway (e.g., JAK2 mutation-driven MPNs), but also in diseases, in which JAKs act as mediators and amplifiers of proinflammatory signals, even though the disease might not be caused by deleterious changes in the JAK-STAT pathway itself. This is the case for RA for which two JAK inhibitors are already FDA and EMA-approved (tofacitinib, baricitinib), and potentially many other inflammatory diseases currently under investigation.
Similarly, understanding of the regulatory mechanisms governing the JAK-STAT pathway has grown steadily. Nevertheless, molecular understanding of JAK activation and inhibition is still far from complete. Detailed elucidation of the mechanisms of JAK inhibition and activation on receptors especially will be key for the development of modulators of JAK activity with novel modes of actions. The need for these kinds of novel inhibitors is great, and the fields of application wide. All current JAK inhibitors ('Jakinibs') target the catalytic ATPbinding site of JH1, which are highly similar between JAKs, making specificity within the JAK family problematic for most inhibitors. Furthermore, current inhibitors cannot distinguish between mutated JAKs (e.g. JAK2 V617F in MPNs) and wild-type JAKs leading to potential side-effects and an inability to eradicate diseases caused by somatic JAK mutations.
Encouragingly development of multiple novel JAK activity-modulator types is already underway. These include covalent inhibitors against JAK3 JH1 [144] , compounds targeting the ATP-binding site of JH2 [145] [146] [147] [148] , protein-protein interaction interfaces within JAK [149] , and the extracellular parts of JAK-associated receptors [91] . These targets have the potential to deliver more specificity (including mutant-specificity over wild-type JAK), as well as safety.
